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 GPR18, a member of the Class A G-Protein Coupled Receptors (GPCRs), is 
recently a de-orphanized receptor, that upon activation has been found to boost the 
immune system.  Although a GPR18 crystal structure has not been solved, a homology 
model of the inactive state (R) of GPR18 was built in the Reggio lab based upon the mu-
opioid x-ray crystal structure.  The present study continues this work by adding loop 
regions and N- and C-termini to the R state model and by developing a model of GPR18 
R* (Active) state, complete with loop regions and N- and C-termini.  The complete 
inactive and active state models were used for docking studies of five known GPR18 
antagonists, 1,3-dimethoxy-5-methyl-2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-
en-1-yl]benzene; 1, (2R,3aS,3bR,5aS,11bS,11cS,13aS)-3a,11b,11c-trimethyl-2-(2-
methylprop-1-en-1-yl)-2,3,3a,3b,4,5,5a,6,11,11b,11c,12,13,13a-
tetradecahydrobenzofuro[4',5':6,7]indeno[1,2-b]indole; 2, (3S,4S,4aR,6aS,12bS,12cS)-4-
((E)-4-methoxy-4-methylpent-2-en-1-yl)-4,12b,12c-trimethyl-
1,2,3,4,4a,5,6,6a,7,12,12b,12c-dodecahydrobenzo[6,7]indeno[1,2-b]indol-3-ol; 3, (Z)-2-
(3-((4-chlorobenzyl)oxy)benzylidene)-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazin-3(2H)-
one; 4, and 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-
diol; 5 and the GPR18 endogenous ligand, N-arachidonylglycine (NAGly).  
Conformational searches were performed on all antagonists using a systematic search 
using the Hartree-Fock method at the 6-31G* level of theory.  Because NAGly is highly 
flexible, its low energy conformations were determined using the Conformational 
Memories method.  All low energy conformations, less than 3.0 kcal/mol, of each ligand 
were docked using Glide into their respective bundles based on the state of the receptor 
each ligand stabilizes.  The key interaction site for all antagonists, an R in TMH5, R5.42, 
anchors each antagonist in the TMH bundle such that rotameric changes in key toggle 
switch residues, F6.48/H6.52, are prevented, thus preventing the activation of the 
receptor.  The extracellular loop 2 (EC2 loop) residue Y160 further stabilizes each 
antagonist in the binding site.  Identified interactions result in Glide scores consistent 
with experimental EC50 data.  The primary interaction site for the agonist, NAGly, was 
TMH2 residue R2.60.  An additional NAGly interaction was identified with the EC2 loop 
residue K174.  Mutation experiments of key residues identified here are underway in a 
collaborator’s lab.  These studies will help confirm the importance of these key residues 
and further our understanding of the receptor. 
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CHAPTER I 
 
INTRODUCTION 
Background 
 GPR18, a member of the Class A G-Protein Coupled Receptors (GPCRs), was 
recently de-orphanized when icosa-5,8,11,14-tetraenoylamino-acetic acid (N-
arachidonoylglycine; NAGly)  was found to be its endogenous ligand.(1) First isolated 
from mouse in 1996,(2) GPR18 is thought to be the elusive abnormal cannabinoid receptor 
(Abn-CBD) identified by Wagner and co-workers.(3) In humans, GPR18 is localized in 
Chromosome 13q32, in the same region as the Epstein-Barr Virus induced receptor 2 
(EBI2)(4,5) and is structurally homologous to it.  Both receptors also have almost identical 
expression rates which have led to the presumption that they might have similar functions 
as immune response initiators.(6) GPR18 is expressed in several locations in the body 
including peripheral blood mononuclear cells (PBMC), lymphoid tissues such as spleen 
and thymus, and moderate expression in brain, testis, ovary, and lung, all of which are 
associated with the immune system.(7) Recent studies have shown that when channel 
catfish were infected with viral strains, GPR18 expression was induced in the kidneys.(7) 
Further studies have shown that GPR18 is significantly expressed in HTLV-1-
transformed cell lines (HUT 102, MT-2, and MT-4) as well as lymphoid cell lines 
(Jurkat, MOLT-4, HUT 78 and Raji) while the non-lymphoid hematopoietic cell lines 
(U937, HL60, and K562) showed no detectable expression.(1) Due to rapidly evolving 
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bacteria, the use of antibiotics as the traditional medical first line defense is being called 
into question.  With immune-compromising diseases such as diabetes on the rise, 
antibiotic resistant strains are a threat to the public health and safety.  This pattern of 
expression suggests that GPR18 may play a role in the immune system and could be a 
valuable drug target for immune-compromising diseases and antibiotic resistant bacterial 
strains. 
 Other serious concerns for public health are neurodegenerative diseases such as 
multiple sclerosis and Alzheimer’s, which are caused by deregulation of receptor cell 
migration to affected areas in the central nervous system (CNS).(8) The migration is 
regulated by microglia, which play a huge role in active immune response in the brain 
against pro-inflammatory and cytotoxic responses.  In quantitative PCR studies, GPR18 
has been shown to be expressed in the mouse microglia cell line BV-2, (9) as well as, 
human endometrial cell line HEC-1B.(10) This suggests that the endocannabinoid system 
has a part in regulating microglial migration.(8) This pattern of expression, in turn, 
suggests that GPR18 could also be a potential pharmaceutical target for various 
inflammatory diseases.  Endometriosis is another condition caused by abnormal cell 
migration in the wall of the uterus causing intense pain and in some cases infertility.(11) 
Recent studies have shown that GPR18 plays some part in the migration of endometrial 
cells.  Through in silico analysis, GPR18 was found to be expressed in primary 
melanoma cells.(12) Further, quantitative PCR studies by Qin and co-workers have shown 
that GPR18 is also expressed in melanoma metastases.(13) Both of these studies show that 
GPR18 is a potential therapeutic target for aggressive skin cancer melanoma.  Therefore, 
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while the exact role of GPR18 in the human body an area of research, its involvement 
and mere presence in so many major areas of the body make it undeniably important for 
further research. 
 GPCRs make up the largest family of transmembrane eukaryotic receptors, 
making them a focus group among receptor studies.  GPCRs are responsible for 
regulating a large portion of cell signaling through signal transduction over cell 
membranes and are included in multiple systems within an organism.  GPCRs are 
important pharmacological targets because they respond to a vast number of factors such 
as light and hormones.(3) 
 The structures of Class A GPCRs include seven transmembrane α-helices 
(TMHs), an extracellular N-terminus, intracellular C-terminus, extracellular (EC) and 
intracellular (IC) loops that connect the TMHs, and a C-terminal helix helical section, 
parallel to membrane, Helix 8 (H8) (see Figure 1).  With GPCRs varying in the number 
of amino acids in their sequences, the Ballesteros-Weinstein numbering and was created 
in 1995 to allow direct comparisons between receptor sequences.(14)  In this system, the 
most highly conserved residue in each TMH is denoted as x.50 where x is the number of 
the helix.  Sequentially left or right of that residue, the number after x will represent the 
next or previous amino acid in the sequence.  As an example, the most conserved residue 
in TMH2 is aspartic acid D2.50.  The residue immediately before this is V2.49 and 
immediately after is L2.51 in the GPR18 sequence.  GPCRs sequences are characterized 
by conserved motifs within each TMH.  These motifs seem to either play a role in the 
function of the receptor or can be used in studying the homology between receptors. 
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Figure 1. Example of Typical GPCR. 
  
 Rhodopsin was the first GPCR to be crystallized.(15)  For this reason, rhodopsin 
formed the basis for homology models of many GPCRs.  These homology models have 
been used to study the binding of ligands and to study receptor function.  Although an 
increasing amount of x-ray crystal structures of GPCRs are becoming available, the 
method of homology modeling is still a useful tool for researchers working on a receptor 
still waiting to be crystallized.  GPR18 is one of many receptors that for various reasons 
has not been crystallized.  Previous work in this lab resulted in the creation of a 
homology model of GPR18 based on the µ-opioid receptor structure.(16) The µ-opioid 
receptor exhibits 54% sequence homology to GPR18 within its TMH regions. 
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GPCR Activation 
 Within each GPCR binding pocket is a set of residues that functions as a “toggle 
switch” that changes conformation upon agonist binding.  The resultant conformational 
change within the binding pocket, leads to a change in the receptor intracellular domains 
that leads to signal transduction.  These binding pocket “toggle switch” residues typically 
include residue 6.48 of the TMH6 CWXP hinge motif and another residue that interacts 
with 6.48, limiting its conformation.  In order for an agonist to activate a GPCR bundle, 
the toggle switch must be “tripped.” The key conformational change in the toggle switch 
involves the χ1 dihedral on W6.48 which starts on residue 6.48 which is at -60° (g+) in 
the inactive state but moves to a   χ1 of 180° (trans) in the activated state.(15) 
 
Figure 2. Toggle Switch between (Left) Inactive and (Right) Active States. 
 
When this occurs, TMH6 is able to straighten in the CWXP hinge region, causing 
the “ionic lock” between R3.50 and E/D6.30 on the intracellular end of the receptor to 
6 
 
break.  The break allows the receptor to open up and expose residues that can interact 
with the C-terminus of the Gα sub-unit of the G protein and causes a cell signal.(3) 
However, when an antagonist binds, the ligand will block this toggle switch 
conformational change, making the receptor unable to accept the G-protein and cell 
signaling will not occur.  Many GPCRs have aromatic residues that modulate 6.48 
conformation.  Another unique characteristic specific to GPR18 is that it lacks the 
E/D6.30 necessary to form an ionic lock to keep the receptor inactive.  Instead of a 
negatively charged residue, there is a positively charged Lys which would be unable to 
interact to R3.50.  Although there is no GPR18 crystal structure to verify, we hypothesize 
that the TMH3/TMH6 IC end may be closed due to a serine at position 6.31 that could be 
involved in a hydrogen bond with R3.50, thereby serving as the “ionic lock.” 
   
Figure 3. Ionic Lock in Inactive Bundle (Left), and Ionic Lock Broken in Active Bundle 
(Right). 
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GPR18 Ligands 
Like most cannabinoid receptors, GPR18 is known to bind small lipophilic 
molecules and lipophilic endogenous ligands.(1,17) Due to this similarity, GPR18 ligands 
have been hypothesized to enter the receptor via the lipid bilayer.  This type of entry has 
also been shown for the CB2 receptor.(15,18) NAGly has been reported to be the GPR18 
endogenous ligand.(1) NAGly is a derivative of the CB1 endogenous ligand, N-
arachidonoyl ethanolamine (AEA).(1) GPR18 is considered a member of the cannabinoid 
receptor family because of its ability to be activated in cell migration assays by the 
atypical cannabinoids Abn-CBD, O-1602, as well as by ∆9-THC.(8) This induced cell 
migration is blocked by O-1918, or cannabidiol (CBD).(8) This has led many researchers 
to believe that GPR18 is the Abn-CBD receptor that George Kunos found in 2003 but 
was never able to cloned.(11) 
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CHAPTER II 
 
HYPOTHESIS AND METHODS 
Goals 
The focus of this thesis was to create working computational models of GPR18 
that could consequently be studied via mutation and molecular dynamics.  This thesis 
project is a continuation of a previous project in which a homology model of the GPR18 
R (Inactive) state was created (16) using the TMH region of the µ-opioid receptor x-ray 
crystal structure.(19) Using this model, a homology model of the GPR18 R* (Active) state 
was created here.  The most dramatic change in the TMH bundle as the receptor moves 
from the R to the R* state is the straightening of TMH6.  Using Conformational 
Memories (CM), the Monte-Carlo/simulated annealing technique, possible GPR18 
TMH6 conformations were calculated in order to select a straightened TMH6 to represent 
the R* state.  The previously discovered GPR18 inactive state binding pocket (16) was 
explored in ligand docking studies of five known antagonists.  In addition, the 
endogenous agonist (NAGly) was docked in the newly created R* bundle.  Interactions 
formed through docking were studied to highlight key binding pocket residues necessary 
for activation or inactivation of the receptor. 
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Methods 
Rotameric States in Amino Acid Side Chains 
Throughout this thesis, the χ1 dihedral of various side chains in the protein will 
use rotameric nomenclature used by Shi et al in 2002 to describe their angle.(20) A trans 
χ1 angle has a heavy atom at the γ position in which view from β-carbon to α-carbon is 
opposite of the backbone nitrogen (180°), making the side chain extend out.  Viewed 
along the same axis, when the γ heavy atom is opposite the backbone carbon, a gauche+ 
(g+) is defined corresponding to an angle of -60°.  In the opposite direction, a gauche- (g-) 
has the γ-carbon heavy atom opposite the α-hydrogen at an angle of +60° (see Figure 4).  
Both g- and g+ have the side chain bent inwards towards the helix backbone. 
 
           
Figure 4. Example of g+, Trans, and g- Conformation in the χ1 Dihedral of a Phe Side 
Chain. 
 
Conformational Searches of Antagonists 
 Complete conformational analyses of the GPR18 antagonists: 1,3-dimethoxy-5-
methyl-2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene; 1, 
(2R,3aS,3bR,5aS,11bS,11cS,13aS)-3a,11b,11c-trimethyl-2-(2-methylprop-1-en-1-yl)-
2,3,3a,3b,4,5,5a,6,11,11b,11c,12,13,13a-tetradecahydrobenzofuro[4',5':6,7]indeno[1,2-
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b]indole; 2, (3S,4S,4aR,6aS,12bS,12cS)-4-((E)-4-methoxy-4-methylpent-2-en-1-yl)-
4,12b,12c-trimethyl-1,2,3,4,4a,5,6,6a,7,12,12b,12c-dodecahydrobenzo[6,7]indeno[1,2-
b]indol-3-ol; 3, (Z)-2-(3-((4-chlorobenzyl)oxy)benzylidene)-6,7-dihydro-5H-
imidazo[2,1-b][1,3]thiazin-3(2H)-one; 4, and 2-[(1R,6R)-6-isopropenyl-3-
methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol; 5 were performed to identify the 
global minimum energy conformation of each compound.  Each compound was built in 
Spartan08 and optimized in the builder module.  A conformational search facility was 
used to generate 7 conformers for the first torsion angle explored.  Starting conformations 
represented sequential increments of 51.4° in the first torsion angle.  Each generated 
conformation was optimized using the Hartree-Fock method at the 6-31G* level of 
theory.  Any high level energy duplicates were eliminated and only unique conformers 
with lower energies were studied further.  This process was repeated for each major 
rotatable bond within each compound.  
Conformational Memories (CM) 
To create a GPR18 activated state model, all possible conformations of TMH6 
were explored using the conformational memories (CM) method.  Due to the highly 
flexible nature of the arachidonic acid portion of the endogenous ligand, NAGly, CM was 
also used to generate a set of low free energy conformers for NAGly.  The CM method 
employs multiple Monte Carlo/simulated annealing random walks and the CHARMM 
(Chemistry at HARvard Molecular Mechanics) force field.(21) The CM method allows 
highly flexible molecules to converge in a fewer number of steps and efficiently 
overcome large energy barriers.  The CM method can give a full picture of the range of 
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conformations allowed for each molecule based on their free energies.  These free 
energies are a sum of both the intrinsic energy of each allowed conformational state and 
the thermodynamically applied energy conformations.  Each conformation chosen are 
selected because they are considered more favorable to another conformation.  These CM 
calculations are performed in two phases, the Exploratory and Biased Annealing Phases. 
 Exploratory phase.  The first phase of CM is to identify the region of 
conformational space that is most probable for each torsion angle and bond angle.  In 
order to do this, a random walk is used.  Each run starts with an initial temperature of 
3000 K and decreases in temperature for 18 steps to a final temperature of 310 K.  Within 
each of these steps, 50,000 Monte Carlo steps are applied to each torsion or bond angle 
being varied.  For each step, two dihedral angles and one bond angle from the entire set 
of variable angles are chosen at random at each temperature and each movement of the 
two torsion angles and the one bond angle are accepted or rejected using the Metropolis 
criterion.(22) If a conformation is accepted in this phase, then it is used to create 
“memories” of each of the accepted torsion angles and bond angles creating a map of the 
accessible conformational space that the molecule can exist in as a function of 
temperature. 
 Biased annealing phase.  Using the map of populated conformation space 
identified in the exploratory phase, the second phase of CM explores torsion angles and 
bond angles that only occur in that “populated conformational space.” Biased annealing 
starts with an initial temperature of 749.4 K and cools to 310 K in seven steps.  The final 
output contained 108 structures at 310 K for TMH6 and 105 structures for NAGly. 
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 CM study of GPR18 TMH6. 
 TMH6.  In TMH6 of Class A CPCRs, there is a conserved flexible hinge motif, 
CWXP.  In GPR18 the motif is CFXP, where the usual “toggle switch” Trp (6.48) is 
replaced with a Phe (6.48).  This residue has been found to be important for activation in 
many GPCRs.  Previous studies have shown that a conformation change in the 6.48 χ1 
from g+  trans induces conformational changes in the receptor that create an opening on 
the intracellular (IC) side of the receptor that allows the G protein to dock with the 
receptor.(20)  In GPR18, H6.52 appears to form the other part of the toggle switch.  This 
residue must undergo a conformational change in the χ1 from g+  trans in order to 
allow F6.48 to undergo its χ1 g+  trans transition.  CM was used to identify a helix that 
would allow the IC end of the bundle to open.  This opening should allow interaction 
with the G protein.  The phi and psi dihedrals of the backbone from i (P6.50) to i-4 
(V6.46) region was allowed to vary ±50° while the rest of the phi and psi dihedrals of the 
backbone were varied ±10°.  Amides were varied ±20° and side chains were varied 
±180°.  Default bond angles were varied ±8° except for special cases like Met C-S-C 
bonds, Tyr C-O-H bonds, and Lys C-N-H which were all varied ±15°. 
Superimposition and Determination of Helices 
 To achieve a packed R* bundle, the GPR18 TMHs of the inactive R bundle were 
pulled apart 2Å away from a central point.  All 108 output conformations from CM were 
superimposed onto the inactive TMH6 in the inactive GPR18 model.  The Cα’s from 
His23 to Leu31 were used as the basis for the superimposition.  
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Once all outputs were superimposed, a helix that was the most straightened and 
had the least amount of steric clashes in the bundle was chosen for the new R* model.  
This new TMH6 also had an F6.48 χ1 of trans.  The result should be a bundle in which 
no possible hydrogen bond between the R3.50 and S6.33 “ionic lock” is possible.  
However, problems arose from the CM outputs not exploring the region of space needed 
to create an opening big enough for the G protein to interact.  Recent studies have 
proposed a tilting of helices may occur during activation to allow the intracellular region 
to open up to accommodate the G protein.(23) With this new information, the EC end of 
the chosen TMH6 was tilted inward 1.5Å.  The movement allowed an appropriate 
intracellular opening. 
Ligand Docking Protocol 
 A total of 5 antagonists and 1 agonist were docked into the R and R* bundles 
respectively.  All low energy conformations identified for each ligand were then docked 
used using the automatic docking program, Glide (Schrodinger Inc.).  From the centroid 
of select residues inside the binding site, Glide generates a grid.(24)  The primary 
interaction site chosen within the binding pocket for Glide docking studies was R5.42 
because of its positive charge and its location near the F6.48/H6.52 toggle switch 
residues.  With the grid generated, Glide is able to explore the binding pocket and find 
the lowest energy ligand/receptor complex.  Glide denotes energy favorable docks with 
low Glide scores.  The ligand/receptor complex with the lowest Glide score was then 
energy minimized using the OPLS 2005 force field, by the same process as described 
below. 
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Minimization Protocol 
 Each ligand/receptor complex was energy minimized using Macromodel 9.9 
(Schrödinger LLC) to a convergence of 0.1 kcal/mol∙Å.  In the active bundle, a distance 
constraint was applied to the α carbon of R3.50 and the α carbon of S6.33 was 
constrained to a distance of 13.4 Å ± 2.5 Å with a force of 1000 kcal/mol∙Å.  All charged 
residues pointing into the bundle where mutated to their neutral forms except for D2.50 
and D7.49 which were solvated with 5 waters.  The χ1 dihedrals for both Y5.58 and 
L6.44 were adjusted to g+ to allow TMH5 and TMH6 to pack.  The minimization 
protocol used the OPLS_2005 force field and a distance dependent dielectric with a 
dielectric constant of 1.  All backbone phi / psi dihedrals were constrained with a force of 
1000 kcal/mol∙Å, while the χ1 dihedrals of the amino acid side chains of each residue 
were allowed to vary.  The energy was allowed to converge to 0.1 kcal/mol, then the 
torsional constraint force was reduced by half and the bundle was minimized again to the 
same gradient.  This sequence was repeated 6 times.  In the 7th stage the torsional 
constraints were eliminated.  An 8.0-Å extended nonbonded cutoff (updated every 10 
steps), a 20.0-Å electrostatic cutoff, and a 4.0-Å hydrogen bond cutoff were used in each 
stage of the calculation.  For each minimization, the ligand was present within the 
binding pocket, to preserve the ligand binding space. 
Loop and Termini Methodology 
 To complete the R* bundle, loop segments and termini were built and added to 
the R* model using Modeller 9.8.  Modeller uses a template library of optimal side chain 
conformations derived from the Protein Data Bank for all amino acids.  Each loop 
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structure is given an objective function ranking value.  This value is assigned based on 
steric interactions and hydrogen bonding of each possible conformation of both the loops 
and the termini.  This Monte Carlo technique developed by Fiser and co-workers (25) 
orders the output to give energy realistic IC and EC loop conformations.  Using the 
CHARMM force field, three sets of loops/termini were run separately and assigned an 
objective function ranking value.(21) The first set contained the 3 IC loops and the C-
terminus, the second contained the three EC loops, and the last was the N-terminus.  By 
simultaneously running the IC loops in a single calculation and EC loops in a single 
calculation, more plausible conformations could be determined in the presence of each 
other.  The N-terminus was calculated separately from the EC loops to find outputs 
appropriate for both with the lowest energies and the desired interactions for the docked 
agonist.  The 300 lowest energy loop outputs from each group were used for further 
analysis. 
Once a final output set of loops were selected, the bundle was refined via two sets 
of minimizations in MacroModel.  The first minimization was run at a high dielectric 
(ε=80; water) with all the transmembrane regions frozen, but loops and termini free to 
move.  After the first minimization, the loop regions, termini and TMH backbones were 
frozen with the TMH residues free to move.  This system was minimized in a low 
dielectric (ε=1) using extended non-bonded cut offs. 
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CHAPTER III 
 
RESULTS 
Ligand Conformational Searches and Docking 
Antagonists 
The binding sites of five antagonists were explored using the previously 
constructed inactive state GPR18 model.  The key interaction site for the antagonists, 
R5.42, positioned the ligands on top of the F6.48/H6.52 toggle switch residues, 
preventing the conformational change associated with activation of the receptor.  Based 
on the functional groups within the structures of each ligand, more interactions were able 
to form in the binding pocket.  The final Glide docking score of each antagonist/GPR18 
R complex followed the trend of IC50 values are displayed in Table 1. 
 
Table 1 
The Five Antagonists with Their IC50/EC50 Values and Their Final Glide Score 
Antagonist Glide Score IC50 
1 -6.06 - 
2 -6.49 9.91 ± 2.59 μM 
3 -6.46 13.4 ± 1.3 μM 
4 -9.97 0.28 ± 0.11 μM 
5 -6.92 - 
*Both 1 and 5 were proven as antagonists through the attenuation of cell migration 
induced by NAGly. 
17 
 
Antagonist 1.  1,3-dimethoxy-5-methyl-2-[(1R,6R)-3-methyl-6-prop-1-en-2-
ylcyclohex-2-en-1yl] benzene (O-1918), 1 has long been known as an antagonist at the 
two former orphan receptors GPR18 and GPR55.  Although there is no IC50 value for this 
compound, Compound 1 was shown to inhibit the NAGly induced migration of BV-2 and 
HEK293-GPR18 transfected cells.(11,13)  Compound 1 has only one crucial rotatable bond 
and was found to have only 2 conformers (Conformer A, global min and Conformer B, 
ΔE= 1.03 kcal/mol; see Figure 5).  Docking studies identified primary interaction site for 
the antagonist to be R5.42.  Here, the interaction was a cation-pi interaction between the 
primary interaction site R5.42 and the aromatic portion of Compound 1 (see Figure 6).  
Another interaction was spotted involving H6.52 which created a pi stacking interaction 
with the same aromatic portion of antagonist 1 giving the dock a Glide score of -6.06 (see 
Figure 7). 
      
Figure 5. O-1918 (1) Conformers. Conformer A: Green; Global Min. Conformer B: Pink; 
ΔE=1.031 Kcal/Mol. 
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Figure 6. Compound 1 Forming a Cation Pi Interaction with the Primary Interaction Site, 
R5.42 and Pi Stacking with H6.52. 
 
Figure 7. Compound 1 above the Inactive State Toggle Switch, Preventing Activation. 
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Antagonists 2 and 3.  Compounds 2 and 3 are marine fungal derived antagonists 
of GPR18 with an IC50 of 9.91 ± 2.59 µM and 13.4 ± 1.3 µM respectively.(26)  Compound 
2 has only one rotatable bond.  Only one conformer was found for 2 due to the limited 
number of rotatable bonds within the structure (see Figure 8).  Inside the binding pocket, 
2 formed a cation pi interaction with R5.42 and a hydrogen bond with the backbone 
carbonyl of F6.51 giving a Glide score of -6.49 (see Figure 9). 
           
Figure 8. 2D Structure of Compound 2 (Left) and the Global Min of Compound 2 
(Right). 
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Figure 9. Cation Pi Interaction with R5.42 and Docked Antagonist 2 and Hydrogen Bond 
with the Backbone of F6.51. 
 
Figure 10. Compound 2 Interacting with the Inactive State Toggle Switch Preventing 
Conformational Change. 
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Compound 3 has four rotatable bonds (see Figure 11).  Conformational analysis 
resulted in 83 conformers.  When the global min of 3 was docked in the inactive state 
bundle, its aromatic ring forms a cation pi interaction with R5.42 along with a hydrogen 
bond with the backbone of F6.51 with a Glide score of -6.46 (see Figure 12). 
           
Figure 11. 2D Structure of Compound 3 (Left), and All Conformations of Compound 3 
Superimposed on the Fused Ring System (Right). 
 
Figure 12. Compound 3 Forming a Cation Pi Interaction with R5.42 and a Hydrogen 
Bond with the Backbone of F6.51. 
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Figure 13. Compound 3 Interacting with the Inactive State Toggle Switch Preventing 
Conformational Change. 
 
Antagonist 4.  Compound 4 is a GPR18 antagonist with an IC50 of 0.279 +/- 
0.111 µM.(27)  Compound 4 has 3 rotatable bonds and produced 25 conformers.  The 
conformers had either an extended conformation or a petal conformation. The lowest 
energy conformers were the extended conformers and the global min was then docked 
into the inactive bundle.  Docking studies indicated that the antagonist forms pi stacking 
interaction with H6.52, while the primary interaction residue forms a cation pi interaction 
with the ligand (see Figure 15).  A hydrogen bond interaction occurs with a carbonyl on 
the antagonist and a residues on the EC2 loop, K174, further holding the ligand in place 
on top of the toggle switch (see Figure 16).  A fourth interaction occurs with the 
chlorobenzene group on antagonist 4 and M7.42 creating a methionine interaction.28  The 
23 
 
antagonist generated the best Glide score of -9.97 due to its multiple interactions within 
the binding pocket (see Table 1). 
 
Figure 14. 2D Structure of Antagonist 4. 
 
Figure 15. Compound 4 Forming a Hydrogen Bond Interaction with K174 and Two Pi 
Interactions with R5.48 and H6.52; Antagonist 4 also Forms a Methionine Interaction 
with M7.42. 
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Figure 16. Antagonist 4 Interacting with the Inactive State Toggle Switch Preventing 
Activation. 
 
Antagonist 5.  Compound 5 is a small molecule that was found to be a GPR18 
antagonist by McHugh et al.(11) and was used as the final antagonist to dock in the 
inactive state receptor model.  Compound 5 has three main rotatable bonds that would 
that governed the conformations of the ligand. 5 produced 8 unique conformers (see 
Figure 17).  When docked, compound 5 formed two hydrogen bond interactions with 
R5.42 and Y174, preventing the toggle switch from changing conformation, giving it a 
Glide score of -6.92 (see Figure 18 and Figure 19). 
 
Figure 17. 2D Structure of Antagonist 5. 
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Figure 18. Docked Compound 5 Forming Hydrogen Bonds with Primary Interaction 
Residue R5.42 and K174. 
 
Figure 19. Compound 5 above the Toggle Switch Residues Preventing Activation. 
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NAGly 
The GPR18 endogenous agonist, NAGly, was chosen as the sixth ligand for the 
docking studies (see Figure 20).  NAGly was identified as the endogenous ligand of 
GPR18 via screening of 198 lipids of the Bioactive Lipid Alignment Library against a 
stable polyclonal population of GPR18-expressing L929 cells and GPR18 stably 
transfected K562 and CHO cells.  This screening used intracellular Ca2+ mobilization as 
the readout.  At a concentration of 10 μM, NAGly induced a significant increase in 
intracellular Ca2+ concentration in GPR18-expressing cells as compared to mock-
transfected cells.(1)  NAGly also inhibited cAMP production in GPR18-transfected CHO 
cells compared to mock-transfected cells with an EC50 of 44.5 nM.(1)  Pretreatment of the 
GPR18-transfected CHO cells with pertussis toxin (PTX) abolished the inhibition of 
forskolin-stimulated cAMP production by NAGly.(1)  These experiments by Kohno and 
co-workers were the first to give solid evidence that NAGly is a natural ligand for GPR18 
and that GPR18 couples to Gi/o proteins.(1) 
 
Figure 20. 2D Structure of Compound 6; NAGly. 
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NAGly has enough rotatable bonds to make a traditional conformational analysis 
intractable.  Instead, we used the Conformational Memories (CM) method, to generate a 
set of low free energy conformers of this ligand.  This method employs multiple Monte 
Carlo/simulated annealing random walks and the CHARMM (Chemistry at HARvard 
Molecular Mechanics) force field.(21)  Similar to previously reported CM results for 
arachidonic acid,(10) NAGly’s conformers could be divided into four groups: linear, U-
shape, J-shape, and helical. 
When measuring the dihedrals in each cluster, NAGly had the same shape-
clusters identified previously for the CB1 endogenous agonist, anandamide.(7)  In general, 
when each angle in a pair has the same sign, that region of the acyl chain will be 
extended.  A pair is considered as any two dihedrals adjacent to another for example ω5, 
consisting of carbons 5-8, and ϖ6, consisting of carbons 6-9.  When the two angles in a 
pair have opposite signs, curvature is introduced into the acyl backbone.  In the J-shape 
(Figure 21), only the (ω5, ϖ6) pair has opposite signs while the first 3 dihedrals and the 
following homoallylic dihedrals have the same sign.  The J-shapes include a subset of 
structures noted as reverse Js where the head group is near the top and the tail curves into 
the J.  In this sub group it is the (ϖ11, ϖ12) pair that has the opposite signs.  In the 
anandamide paper, for the helical shape (Figure 21), (ϖ5, ϖ6), (ϖ8, ϖ9), and (ϖ11, ϖ12) 
each had opposite signs.  However, our findings indicate that the helical conformers only 
needed to have at least two dihedrals adjacent to each other with opposite signs to form a 
helical-like acyl backbone.  In the U-shape (Figure 21), (ϖ5, ϖ6) and (ϖ11, ϖ12) have 
opposite signs which induced curvature near the ends of the molecule rendering it U-
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shaped.  Most of the conformers fit this pattern however there were some structures that 
did not.  The outliers did have dihedrals in the (ϖ1-ϖ3) that had the same signs then a 
pair or two in between with opposite signs that induced a curve followed by another pair 
with the same sign that created the last U-arm.  For the last group, the extended 
conformers we also see that all three pairs of dihedrals have the same sign as their 
counter within the pair, although there as a few outliers that only contain two pairs with 
the same sign.  For these outliers the pairs are adjacent to each other which still allowed 
the conformer to extend.  
 
Figure 21. The Four Conformational Shapes NAGly Adopted in its CM Output with 
Their Percent Occurrence. 
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Table 2 
Torsion Angles of NAGly 
Torsion Angle Corresponding Carbons 
ω5 C5, C6, C7, C8 
ω6 C6, C7, C8, C9 
ω8 C8, C9, C10, C11 
ω9 C9, C10, C11, C12 
ω11 C11, C12, C13, C14 
ω12 C12, C13, C14, C15 
ω16 C16, C17, C18, C19 
 
Before loops could be added to the bundle, NAGly was docked into the newly 
modified R* bundle.  By doing this, the bundle could be minimized around the 
endogenous ligand in the binding pocket.  The primary interaction site for NAGly at 
GPR18 was found to be another arginine, R2.60, on the opposite side of the bundle from 
the antagonists’ primary interaction site.  Here, a hydrogen bond is formed between the 
NAGly carboxylic oxygen and R2.60 on TMH2.  Another hydrogen bond between 
NAGly’s carbonyl group and the EC2 loop residue, K174, is also formed (see Figure 22).  
This binding site permits the conformational change in the toggle switch associated with 
activation (see Figure 23). 
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Figure 22. NAGly Docked into the Active State Bundle Showing the Electrostatic 
Interactions between R2.60 and Kl74 in the EC2 Loop. 
 
Figure 23. NAGly Positioned above the Already Activated Toggle Switch Residues. 
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GPR18 R* Model Based on GPR18 R Model 
 Using the previously constructed GPR18 (R) structure as a template, an active 
(R*) bundle was constructed.  The transition from the inactive to active state for Class A 
GPCRs, involves a conformational change in TMH6 that causes the IC end of TMH6 to 
move away from the TMH bundle, breaking the ionic lock between the IC ends of TMH3 
and TMH6.  Figure 24 shows the CM output for GPR18 TMH6 with the EC ends of the 
helices superimposed.  The cyan colored conformer was chosen for incorporation in the 
R* GPR18 model.  Figure 25 illustrates the conformational differences between the final 
GPR18 R and R* models. 
 
Figure 24. IC View of CM Output of TMH6, Blue Helix was Selected for R* Bundle 
(Left); View from the Lipid Bilayer of CM Output of TMH6, the Cyan Helix was 
Selected (Right). 
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Figure 25. IC (Left) and Lipid Bilayer View of TMH6 in Inactive Conformation (Green) 
and Active Conformation (Blue) (Right). 
 
Loop and Termini Construction and Modeling 
Intracellular (IC) Loops and C Terminus 
The loops were built in Maestro and connected to the bundle with as minimal 
steric clash as possible.  Using Modeller, two groups of loops were run to calculate all 
possible conformers, in a high dielectric which simulates an aqueous biological 
environment.  The first group contained the three IC loops and the C terminus, while the 
second group contained the three EC loops and the N terminus.  The IC loops and the C 
terminus were run first because they had fewer constraints in their conformations.  The 
intracellular loops for GPR18 where relatively small compared to the extracellular loops 
which limited the number of conformations the loops could take.  Also, unlike the EC 
loops; there were no disulfide bonds that would play a part in the final loop conformation.  
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Using the same Modeller settings, conformations of all three IC loops and the C terminus 
were run together so that their outputs would incorporate conformations with respect to 
each other and minimize steric clash.  Due to the lack of any mutation data on the IC loop 
and C terminus of GPR18, there was no specific loop or terminus conformation in mind.  
Once the loops were modeled, the output was analyzed for a set of low energy 
conformations that would not block a G protein from inserting into the IC end of the 
bundle and displayed a C-terminus conformation consistent with the presence of a lipid 
bilayer.  Once an appropriate output was selected, all three loops and the c terminus was 
attached to the active bundle. 
Extracellular (EC) Loops 
Once the appropriate IC loops were added to the bundle, the EC loops 
conformations were calculated using Modeller with the same settings as the IC loops.  
Both the EC1 and EC3 loops were relatively small with 5 and 6 residues respectively.  
The EC2 loop, however, is much longer with 26 residues.  Cys172 on EC2 loop is also 
part of an important disulfide bond with Cys3.25 (94) on TMH3, which was the only 
structural constraint specified.  In all published x-ray crystal structures of Class A GPCRs 
containg a disulfide bridge between a Cys in EC-2 and a Cys at position 3.25 in the 
receptor, the second EC-2 residue after the Cys faces down into the ligand binding 
pocket.  This was used to screen possible EC-2 loops for the GPR18 model. The EC-2 
loop conformation incorporated into the model had Lys174 facing into the binding 
pocket.  The chosen loops and sidechains were then minimized in a high dielectric. 
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N Terminus 
The N Terminus of GPR18 contains 19 residues.  Modeller was used to calculate 
a conformation of this terminus in a high 2.8 dielectric to simulate the aqueous 
environment.  No structural restrictions were put on the N terminal segment, but outputs 
were selected based on conformations with respect to the lipid bilayer.  Any 
conformations that had the terminus dipping into the lipid bilayer were immediately 
rejected.  Overall, an output was chosen that draped over the top of the bundle.  This 
would allow ligands to enter into the binding pocket from the lipid bilayer without 
interference, but would preclude entrance from the extracellular milieu. 
Summary 
A homology model of the active state of the GPR18 receptor was constructed 
using a recently built homology model of the receptor in its inactive state.  
Conformational Memories was used to explore all possible conformers of TMH6.  A 
more straightened conformer of TMH6 was chosen for the activated state model.  This 
conformer precludes the TMH6 from forming the ionic lock between S6.33 and the 
conserved R3.50.  Without the ionic lock, the receptor would not be able to stabilize its 
inactive state allowing the extracellular end to open up and promote an interaction with 
the G protein.  With the two bundles (both inactive and active) completed, several known 
GPR18 antagonists and the endogenous ligand were selected to be docked into the 
bundles to explore their key interactions.  All five of the antagonists’ conformational 
searches were done using Spartan while conformations of the endogenous ligand were 
found using Conformational Memories.  All identified low energy conformers of each 
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ligand were docked using Glide into their respective bundles.  The key interaction site for 
the antagonists, R5.42, positioned the ligands above the binding site toggle switch 
residues (F6.48 and H6.52) preventing the activation of the receptor.  Other residues, like 
Y160, further stabilized a ligand in this binding site.  Glide scores for the 5 antagonists 
followed the trend in their IC50 values (Table 1).  The primary interaction site for the 
agonist, NAGly, was found to be R2.60.  Interaction of the head group of NAGly with 
R2.60, gave the ligand enough docking room such that the toggle switch residues (F6.48 
and H6.52) were unconstrained and therefore transition to the active state was possible.  
Another interaction between NAGly and EC-2 loop residue, K174, also helped anchor the 
ligand at GPR18.  Mutation studies currently in progress in Dr. Mary Abood’s lab will 
test the importance of the interaction site residues identified here and further our 
understanding of GPR18. 
 
  
36 
 
 
WORKS CITED 
1. Kohno, M., Hasegawa, H., Inoue, A., Muraoka, M., Miyazaki, T., Oka, K., and 
Yasukawa, M. (2006) Identification of N-arachidonylglycine as the endogenous 
ligand for orphan G-protein-coupled receptor GPR18. Biochemical and 
biophysical research communications 347, 827-832 
 
2. Gantz, I., Muraoka, A., Yang, Y. K., Samuelson, L. C., Zimmerman, E. M., Cook, 
H., and Yamada, T. (1997) Cloning and chromosomal localization of a gene 
(GPR18) encoding a novel seven transmembrane receptor highly expressed in 
spleen and testis. Genomics 42, 462-466 
 
3. Weis, W. I., and Kobilka, B. K. (2008) Structural insights into G-protein-coupled 
receptor activation. Current opinion in structural biology 18, 734-740 
 
4. Hamm, H. E., Deretic, D., Arendt, A., Hargrave, P. A., Koenig, B., and Hofmann, 
K. P. (1988) Site of G protein binding to rhodopsin mapped with synthetic 
peptides from the alpha subunit. Science 241, 832-835 
 
5. Devane, W. A., Dysarz, F. A., 3rd, Johnson, M. R., Melvin, L. S., and Howlett, A. 
C. (1988) Determination and characterization of a cannabinoid receptor in rat 
brain. Molecular pharmacology 34, 605-613 
 
6. Li, S., Huang, S., and Peng, S. B. (2005) Overexpression of G protein-coupled 
receptors in cancer cells: involvement in tumor progression. International journal 
of oncology 27, 1329-1339 
 
7. Pridgeon, J. W., and Klesius, P. H. (2013) G-protein coupled receptor 18 (GPR18) 
in channel catfish: expression analysis and efficacy as immunostimulant against 
Aeromonas hydrophila infection. Fish & shellfish immunology 35, 1070-1078 
 
8. McHugh, D., Hu, S. S., Rimmerman, N., Juknat, A., Vogel, Z., Walker, J. M., and 
Bradshaw, H. B. (2010) N-arachidonoyl glycine, an abundant endogenous lipid, 
potently drives directed cellular migration through GPR18, the putative abnormal 
cannabidiol receptor. BMC neuroscience 11, 44-58 
 
9. Yin, H., Chu, A., Li, W., Wang, B., Shelton, F., Otero, F., Nguyen, D. G., 
Caldwell, J. S., and Chen, Y. A. (2009) Lipid G protein-coupled receptor ligand 
identification using beta-arrestin PathHunter assay. The Journal of biological 
chemistry 284, 12328-12338 
37 
 
10. Barnett-Norris, J., Guarnieri, F., Hurst, D. P., and Reggio, P. H. (1998) 
Exploration of biologically relevant conformations of anandamide, 2-
arachidonylglycerol, and their analogues using conformational memories. Journal 
of medicinal chemistry 41, 4861-4872 
 
11. McHugh, D., Page, J., Dunn, E., and Bradshaw, H. B. (2012) Delta(9) -
Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 
receptors and induce migration in human endometrial HEC-1B cells. British 
journal of pharmacology 165, 2414-2424 
 
12. Qin, Y., Verdegaal, E. M., Siderius, M., Bebelman, J. P., Smit, M. J., Leurs, R., 
Willemze, R., Tensen, C. P., and Osanto, S. (2011) Quantitative expression 
profiling of G-protein-coupled receptors (GPCRs) in metastatic melanoma: the 
constitutively active orphan GPCR GPR18 as novel drug target. Pigment cell & 
melanoma research 24, 207-218 
 
13. Gatley, S. J., Gifford, A. N., Volkow, N. D., Lan, R., and Makriyannis, A. (1996) 
123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain 
cannabinoid CB1 receptors. European journal of pharmacology 307, 331-338 
 
14. Ballesteros, J. A. Weinstein, H. (1995) Integrated Methods for the Construction of 
Three-Dimensional Probing of Structure-Function Relations in G Protein-Coupled 
Receptors. In Methods in Neurosciences 25, 366-429 
 
15. Hurst, D. P., Grossfield, A., Lynch, D. L., Feller, S., Romo, T. D., Gawrisch, K., 
Pitman, M. C., and Reggio, P. H. (2010) A lipid pathway for ligand binding is 
necessary for a cannabinoid G protein-coupled receptor. The Journal of biological 
chemistry 285, 17954-17964 
 
16. Schmeisser, M. G. (2013) Creation of a GPR18 Homology Model Using 
Conformational Memories. in Chemistry, University of North Carolina at 
Greensboro 
 
17. Li, J., Edwards, P. C., Burghammer, M., Villa, C., and Schertler, G. F. (2004) 
Structure of bovine rhodopsin in a trigonal crystal form. Journal of molecular 
biology 343, 1409-1438 
 
18. Pei, Y., Mercier, R. W., Anday, J. K., Thakur, G. A., Zvonok, A. M., Hurst, D., 
Reggio, P. H., Janero, D. R., and Makriyannis, A. (2008) Ligand-binding 
architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-
specific binding motif and modeling GPCR activation. Chemistry & biology 15, 
1207-1219 
 
38 
 
19. Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., 
Sunahara, R. K., Pardo, L., Weis, W. I., Kobilka, B. K., and Granier, S. (2012) 
Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. 
Nature 485, 321-326 
 
20. Shi, L., Liapakis, G., Xu, R., Guarnieri, F., Ballesteros, J. A., and Javitch, J. A. 
(2002) Beta2 adrenergic receptor activation. Modulation of the proline kink in 
transmembrane 6 by a rotamer toggle switch. The Journal of biological chemistry 
277, 40989-40996 
 
21. Whitnell, R. M., Hurst, D. P., Reggio, P. H., and Guarnieri, F. (2008) 
Conformational memories with variable bond angles. Journal of computational 
chemistry 29, 741-752 
 
22. Zhang, R., Hurst, D. P., Barnett-Norris, J., Reggio, P. H., and Song, Z. H. (2005) 
Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is 
accessible within the ligand binding crevice: evidence for possible CB2 deviation 
from a rhodopsin template. Molecular pharmacology 68, 69-83 
 
23. Ahuja, S., Hornak, V., Yan, E. C., Syrett, N., Goncalves, J. A., Hirshfeld, A., 
Ziliox, M., Sakmar, T. P., Sheves, M., Reeves, P. J., Smith, S. O., and Eilers, M. 
(2009) Helix movement is coupled to displacement of the second extracellular 
loop in rhodopsin activation. Nature structural & molecular biology 16, 168-175 
 
24. Kotsikorou, E., Madrigal, K. E., Hurst, D. P., Sharir, H., Lynch, D. L., Heynen-
Genel, S., Milan, L. B., Chung, T. D., Seltzman, H. H., Bai, Y., Caron, M. G., 
Barak, L., Abood, M. E., and Reggio, P. H. (2011) Identification of the GPR55 
agonist binding site using a novel set of high-potency GPR55 selective ligands. 
Biochemistry 50, 5633-5647 
 
25. Fiser, A., Do, R. K., and Sali, A. (2000) Modeling of Loops in Protein Structures. 
Protein Science : a publication of the protein society 9, 1753-1773 
 
26. Harms, H., Rempel, V., Kehraus, S., Kaiser, M., Hufendiek, P., Muller, C. E., and 
Konig, G. M. (2014) Indoloditerpenes from a marine-derived fungal strain of 
Dichotomomyces cejpii with Dntagonistic activity at GPR18 and cannabinoid 
receptors. Journal of natural products 77, 673-677 
 
27. Rempel, V., Atzler, K., (2014) Bicyclic imidazole-4-one derivatives: a new class 
of antagonists for orphan G protein-coupled receptors GPR18 and GPR55. Med. 
Chem. Commun. 
 
39 
 
28. Valley, C., Cembran, A., (2012) The Methionine-aromatic Motif Plays a Unique 
Role in Stabilizing Protein Structure. Journal of Biological Chemistry 287, 34979 
–34991 
  
40 
 
APPENDIX A 
 
GPR18 ANTAGONISTS AND AGONIST 
 
 
 
 
 
 
 
41 
APPENDIX B 
 
GPCR SEQUENCE ALIGNMENT 
 
 
 
 
